Jan. 13 at 2:58 PM
$PLX https://protalixbiotherapeutics.gcs-web.com/static-files/465d2891-4135-42e5-8581-f24e175cb07f?utm_source=chatgpt.com
1) For once, I'm pleased to have anticipated whoever (Chiesi?) deleted the poster referring to the 5-year cardiac results of the F03 trial, which was available on the Protalix website. I had saved it, and now I'm reposting the summary data as it was reported, with a brief final comment.
"Cardiac Outcomes • Based on cardiac MRI, no cardiac fibrosis developed over 60 months of treatment • At month 60, mean LVMI (SE) had increased in women by 13.6 g/m2 (5.3) compared with 5.7 g/m2 (2.2) in men; the mean values for both groups were within normal ranges • LVM showed a slight increase at month 60 but all values remained normal • EF was stable over 60 months of treatment, with a mean (SE) decrease at month 60 of 0.5% (1.4) • Of the cardiac parameters that were assessed by echocardiography (PR, QRS, and QT durations) and stress test (chest pain, dizziness, palpitations, shortness of breath, other), most remained stable and within normal ranges •
